Alexion Pharmaceuticals, Inc. (ALXN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN)

ALXN 182.50

0.0%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (375)	11/5/2003 6:31:19 PM
From: Icebrg	Read Replies (2) of 824

Eculizumab, a C5 Complement-Blocking Antibody, Controls Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) with Responses Maintained over a Prolonged Period of Therapy. Session Type: Poster Session 29-II abstracts2view.com An abstract at ASH (registration required) indicates continuing very good results in PNH. In summary, this study demonstrates that eculizumab is well tolerated, dramatically decreases hemolysis and transfusion requirement as well as improving the symptoms of PNH. The effectiveness of eculizumab has been maintained for a median of 12 months of therapy and is ongoing in all patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next